We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.54B
AUM Growth
+$55.8M
Cap. Flow
-$1.48B
Cap. Flow %
-15.48%
Top 10 Hldgs %
82.65%
Holding
142
New
10
Increased
13
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$28.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.1M
3
MRUS
Merus
MRUS
+$9.82M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$6.94M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.88M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$274M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
3
OMER icon
Omeros
OMER
+$11.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.52M
5
IMGN
Immunogen Inc
IMGN
+$9.01M

Sector Composition

Rank Sector Weight
1 Healthcare 86.04%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMTX
51
DELISTED
Dimension Therapeutics, Inc
DMTX
$7.51M 0.08%
1,251,881
– –
AIMT
52
DELISTED
Aimmune Therapeutics
AIMT
$7.29M 0.08%
673,908
+423,908
+170% +$5.76M
VTAE
53
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$6.88M 0.07%
637,597
– –
SAGE
54
DELISTED
Sage Therapeutics
SAGE
$6.75M 0.07%
224,048
– –
AKTX
55
Akari Therapeutics
AKTX
$15.3M
$6.7M 0.07%
621
+126
+25% +$1.62M
PRQR icon
56
ProQR Therapeutics
PRQR
$330M
$5.97M 0.06%
1,234,095
-115,624
-9% -$595K
NTRA icon
57
Natera
NTRA
$47.9B
$5.43M 0.06%
450,000
– –
ALDR
58
DELISTED
Alder Biopharmaceuticals
ALDR
$5.43M 0.06%
+217,328
New +$5.88M
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.55B
$5.42M 0.06%
110,894
-13,000
-10% -$841K
ARWR icon
60
Arrowhead Research
ARWR
$12.3B
$5.37M 0.06%
1,009,509
– –
CNCE
61
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.28M 0.06%
470,058
-25,850
-5% -$329K
AERI
62
DELISTED
Aerie Pharmaceuticals
AERI
$5.27M 0.06%
299,356
– –
NERV icon
63
Minerva Neurosciences
NERV
$231M
$5.19M 0.05%
+63,551
New +$4.04M
NDRM
64
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.96M 0.05%
305,000
– –
GNMX
65
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.89M 0.05%
880,539
+115,539
+15% +$607K
SYRS
66
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.71M 0.04%
+20,447
New +$3.71M
CPRX
67
DELISTED
Catalyst Pharmaceutical
CPRX
$3.64M 0.04%
5,122,153
-376,306
-7% -$303K
MCRB icon
68
Seres Therapeutics
MCRB
$45.8M
$3.63M 0.04%
6,250
– –
ECYT
69
DELISTED
Endocyte, Inc. Common Stock
ECYT
$3.63M 0.04%
1,130,577
-565,288
-33% -$2.07M
LOXO
70
DELISTED
Loxo Oncology, Inc
LOXO
$3.19M 0.03%
137,735
– –
CRIS icon
71
Curis
CRIS
$3.83M
$3.12M 0.03%
1,000
– –
RXDX
72
DELISTED
Ignyta, Inc.
RXDX
$3.1M 0.03%
571,000
– –
JUNO
73
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.08M 0.03%
80,000
– –
TRVN
74
DELISTED
Trevena, Inc.
TRVN
$2.83M 0.03%
720
– –
CBIO
75
Crescent Biopharma
CBIO
$637M
$2.77M 0.03%
+3,812
New +$2.63M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2016 Portfolio in Review

As of Q2 2016, Julian Baker held 142 positions worth $9.54B, up 0.59% from $9.48B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker withdrew a net $1.48B in Q2 2016, closing 7 positions and reducing 15 holdings. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $274M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in Intellia Therapeutics worth $22.7M.

  • Julian Baker's largest Q2 2016 buy was Intellia Therapeutics: 1,062,120 shares worth $22.7M.
  • Julian Baker added most to Acadia Pharmaceuticals in Q2 2016, an estimated $10.1M increase.
  • Julian Baker's biggest Q2 2016 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $15.9M.
  • Julian Baker fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $274M.
  • Julian Baker's ten largest holdings make up 83% of its $9.54B portfolio in Q2 2016.
  • Julian Baker opened 10 new positions and closed 7 in Q2 2016.
  • Julian Baker's portfolio value rose 0.59% quarter-over-quarter to $9.54B.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.